Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers

Targeted therapies for prostate, breast, and ovarian cancers are based on their activity against primary tumors rather than their anti‐metastatic activity. Consequently, there is an urgent need for new agents targeting the metastatic process. Emerging evidence correlates in vitro and in vivo cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Sananes, Amiram, Cohen, Itay, Allon, Irit, Ben‐David, Oshrit, Abu Shareb, Raghda, Yegodayev, Ksenia M., Stepensky, David, Elkabets, Moshe, Papo, Niv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620120/
https://www.ncbi.nlm.nih.gov/pubmed/37609678
http://dx.doi.org/10.1002/1878-0261.13513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620120/
https://www.ncbi.nlm.nih.gov/pubmed/37609678
http://dx.doi.org/10.1002/1878-0261.13513

Ejemplares similares